secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001753926-24-000521
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chromocell presents pipeline update at Sidoti conference, plans Phase 2a for CC8464
--------------------------------------------------------------------------------

- Phase 1 of CC8464 completed; 6 of 159 subjects (4%) experienced a rash; FDA accepted dose-escalation plan to reduce incidence.
- Plans Phase 2a proof-of-concept in idiopathic small fiber neuropathy (~240 patients) and open-label erythromelalgia study (N=10).
- Eye pain program: developing a CC8464 eye drop; pre-clinical ophthalmologic safety studies and POC in PRK surgery patients planned.
- Sublingual programs: exclusive worldwide license from Benuvia for diclofenac, rizatriptan, ondansetron; 505(b)(2) regulatory pathway.
- Company presented at Sidoti Small Cap Conference on March 13, 2024, with CEO Frank Knuettel and CMO Eric Lang.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624000521/0001753926-24-000521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624000521/g084118_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-000521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer